Lymphoma, B-Cell News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Boston cancer centers certified for gene-altering lymphoma therapy - MassLive.com



MassLive.com
 
Boston cancer centers certified for gene-altering lymphoma therapy 
MassLive.com
According to the FDA release on approval of Yescarta, "The safety and efficacy of Yescarta were established in a multicenter clinical trial of more than 100 adults with refractory or relapsed large B-cell lymphoma. The complete remission rate after ...

 


CAR T-cell therapy approved for B-cell lymphomas may save 'thousands of lives' in next few years - Healio



STAT
 
CAR T-cell therapy approved for B-cell lymphomas may save 'thousands of lives' in next few years 
Healio
The indication includes patients with diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL that arises from follicular lymphoma. The agent is not indicated for the treatment of patients with ...
FDA approves Kite's CAR-T cell therapy; another win for NCI's intramural program The Cancer Letter Publications

all 4 news articles » 


Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market Overview, Comparative Analysis and development forecast ... - MilTech



Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market Overview, Comparative Analysis and development forecast ... 
MilTech
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, ...

and more » 


Coexistence of diffuse large B-cell lymphoma, follicular lymphoma does not worsen prognosis - Healio



Coexistence of diffuse large B-cell lymphoma, follicular lymphoma does not worsen prognosis 
Healio
Patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis did not have worse prognoses than patients with de novo DLBCL, according to study results. DLBCL is often identified at diagnosis of follicular lymphoma. The observation ...

 


Poor Outcomes in Elderly Patients After Treatment Failure in B-Cell Lymphomas - Cancer Network



Poor Outcomes in Elderly Patients After Treatment Failure in B-Cell Lymphomas 
Cancer Network
A study examining treatment and outcome patterns following failure of initial treatment for B-cell lymphoma found that rituximab can improve outcomes regardless of which initial therapy was used, but elderly patients, including those treated with an R ...

 


Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017 - PR Newswire (press release)



DailyHover
 
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017 
PR Newswire (press release)
GlobalData's clinical trial report, "Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017" provides an overview of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) clinical trials scenario. This report provides top line data ...
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) ? Diseases & Therapeutic Areas Global Clinical Trials Review, H2 ... Medgadget (blog)

all 39 news articles » 


Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ... - PR Newswire (press release)



Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ... 
PR Newswire (press release)
TARRYTOWN, N.Y., Nov. 1, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 1 clinical trials of REGN1979 and cemiplimab (REGN2810) in patients with different forms of B-cell lymphoma ...

and more » 


New Research Looks at Role of Metabolic Environment in Aggressiveness of Hodgkin Lymphoma and Diffuse Large B ... - OncLive



New Research Looks at Role of Metabolic Environment in Aggressiveness of Hodgkin Lymphoma and Diffuse Large B ... 
OncLive
Two studies focusing on the role of the metabolic profiles of Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma have been accepted for publication in Seminars in Oncology. These studies have been led by Ubaldo Martinez-Outschoorn, MD, Associate ...

 


New lymphoma treatment developed at Cardiff University - BBC News



BBC News
 
New lymphoma treatment developed at Cardiff University 
BBC News
Lymphomas arise when immune cells called lymphocytes become cancerous. There are two types of lymphocytes - B-cells and T-cells. Recent developments have transformed the once fatal diagnosis of B-cell lymphoma into a curable condition.

and more » 


Mayo Clinic to Offer CAR T-Cell Therapy for Relapsed Non-Hodgkin Lymphoma - Newswise (press release)



Mayo Clinic to Offer CAR T-Cell Therapy for Relapsed Non-Hodgkin Lymphoma 
Newswise (press release)
Newswise ? ROCHESTER, Minn. ? Mayo Clinic announced today that its Rochester campus is one of 16 cancer centers nationally selected to provide chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with B-cell non-Hodgkin lymphoma ...

and more »